MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.15
-0.35
-3.04%
Closed 16:02 05/29 EDT
OPEN
11.48
PREV CLOSE
11.50
HIGH
11.48
LOW
10.84
VOLUME
253.72K
TURNOVER
--
52 WEEK HIGH
31.46
52 WEEK LOW
5.97
MARKET CAP
362.84M
P/E (TTM)
-7.1328
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XENT stock price target is 13.20 with a high estimate of 15.00 and a low estimate of 10.00.

EPS

XENT News

More
Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
Business Wire · 5d ago
SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to $15
SVB Leerink maintains Intersect ENT (NASDAQ:XENT) with a Market Perform and raises the price target from $13 to $15.
Benzinga · 05/12 17:00
JP Morgan Maintains Overweight on Intersect ENT, Lowers Price Target to $18
JP Morgan maintains Intersect ENT (NASDAQ:XENT) with a Overweight and lowers the price target from $28 to $18.
Benzinga · 05/12 15:17
Canaccord Genuity Downgrades Intersect ENT to Hold
Canaccord Genuity downgrades Intersect ENT (NASDAQ:XENT) from Buy to Hold.
Benzinga · 05/12 11:15
Intersect ENT (XENT) Q1 2020 Earnings Call Transcript
Motley Fool · 05/12 09:31
Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/12 02:53
Intersect ENT EPS misses by $0.08, misses on revenue
Intersect ENT (NASDAQ:XENT): Q1 GAAP EPS of -$0.54 misses by $0.08. Revenue of $19.83M (-25.6% Y/Y) misses by $2.86M. Press Release
seekingalpha · 05/11 16:09
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 12:25

Industry

Medical Equipment, Supplies & Distribution
+1.27%
Healthcare Equipment & Supplies
+1.33%

Hot Stocks

Symbol
Price
%Change

About XENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
More

Webull offers kinds of Intersect ENT Inc stock information, including NASDAQ:XENT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENT stock news, and many more online research tools to help you make informed decisions.